N/A N=306 Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness
Human Immunodeficiency Virus
Primary: Index Client Fidelity Assessment — 66.30; 45.70 score on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=87 Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function
Known or Suspected Focal Liver Lesions · Severe Renal Impairment
Primary: Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRI — 2.51; 3.46; 3.00; 3.80 score on a scale — p=<0.001
N/A N=1,127 Optimize PRO Study
Symptomatic Aortic Stenosis
Primary: All-cause Mortality or All-stroke — 5.1; 2.7 Percent of Participants (K-M Rate)
N/A N=2,076 Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
Atrial Fibrillation
Primary: Time to Diagnose NVAF by Each OAC Treatment — 71; 324; 218; 406 Days
N/A N=150 Brain and Meditation (BAM) Study
Stress · Behavior
Primary: Change in Perceived Stress Scale (PSS) Score — 15.0; 17.1; 13.5; 17.1 score on a scale
N/A N=42 The TARANG Intervention
Feasibility · Acceptability · Family Planning
Primary: Feasibility of the Intervention — 28 Participants
Phase 2 N=212 A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
Post-Traumatic Stress Disorder
Primary: Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth…
N/A N=4 Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke
Stroke
Primary: Change in Cortical Excitability Using Single TMS Pulses — -.07667; 0.11; -.05667; .1233 Log10(microvolts)
Phase 2 N=24 An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
Dermatomyositis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 7; 13; 20 Participants
N/A N=11 EarGenie: Assessment of a Minimum Viable Product
Hearing Impaired Children
Primary: Prevalence of Significant fNIRS Detection and Discrimination Responses — 4; 6; 1; 9 Participants
N/A N=369 Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Nonmelanoma Skin Cancer
Primary: Absence of Local Recurrence at Treatment Site(s) Greater or Equal to 3 Years Follow-up — 188; 181; 187; 181 participants
N/A N=20 Visual Outcomes of Vivity in Patients With High Axial Length
Cataract
Primary: Binocular Uncorrected Distance Visual Acuity (logMAR) — -0.1 logMAR
Phase 2 N=300 A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Syndrome
Primary: Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness. — -0.7; -0.5; -0.4 units on a scale
Phase 2 N=86 A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
Parkinson Disease · Cognitive Dysfunction
Primary: Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score — 2.0; 2.0 score on a scale — p=0.9934
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants